<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Tue, 09 Jun 2026 10:02:58 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[医学] AstraZenecaの経口GLP-1薬elecoglipronのPh2試験2つの論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110019&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110019&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 10:02:58 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110019&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Lillyの経口GLP1薬orforglipronがFarxigaに勝った糖尿病Ph3試験論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110018&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110018&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 09:32:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110018&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Novo社のCagriSemaの2型糖尿病治療の取り柄を示したPh3試験一揃い論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110017&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110017&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 06:55:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110017&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Lillyの3G薬retatrutideが2型糖尿病患者体重を多ければ15%減らしたPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110016&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110016&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 16:48:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110016&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Bayerの慢性腎疾患薬Kerendiaが無作為化試験3つまとめ解析で死亡さえ減らした</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110015&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110015&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 16:21:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110015&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Novartisの取り急ぎ承認IgA腎症薬が肝心要のeGFR目標を逃したPh3試験論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110014&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110014&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 15:54:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110014&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ワクチン接種サルから見つかった抗体がマウスのエンテロウイルスD68感染予防</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110013&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110013&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 14:47:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110013&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] HIV感染T細胞のCD4+からCD8+への転身を発見〜CD8+T細胞にもHIVが潜みうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110012&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110012&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 12:39:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110012&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] TDP-43を介したmRNAスプライシングを受ける神経興奮従事遺伝子一揃いを発見</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110011&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110011&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 12:19:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110011&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ホスファチジルセリンを表面に密に纏った血小板で速やかな止血を促しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110010&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110010&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 11:39:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110010&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 【増補版】拒食症患者の7割ほどに脂肪中心のケトン食が有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110009&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110009&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 10:51:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110009&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 神経性無食欲（拒食症）患者の7割ほどが脂肪中心のケトン食で回復</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110008&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110008&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 16:33:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110008&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 肺の微生物組成の乱れを減らすTLR5活性化が特発性肺線維症の治療法となりうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110007&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110007&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 09:57:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110007&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] クローディン1（CLDN1）阻害で胆管癌増殖阻止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110006&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110006&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 07:58:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110006&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] SanofiがOwkinのAI科学者K Proを手足とする自ずと働くAIを開発して導入する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110005&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110005&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 07:19:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110005&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Rocheの抗CD20抗体obinutuzumabで原発性膜性腎症患者の4割弱37%が完全寛解</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110004&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110004&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 16:51:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110004&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 非糖尿病患者腎機能値eGFR年換算低下をBayerのKerendiaがプラセボ差引0.7抑制</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110003&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110003&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 13:55:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110003&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Pfizerが中国Chai Discovery社の人工知能（AI）利用創薬に取り組む</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110002&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110002&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 12:08:49 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110002&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Zenas社のCD19-FcγRIIb両取り抗体がIgG4病フレアを56%減らしたPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110001&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110001&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 11:20:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110001&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] リウマチ性多発筋痛症再発患者の4割ほどがNovartisのCosentyxで持続寛解</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110000&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110000&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 10:22:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110000&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 大塚製薬のAPRIL阻害抗体VoyxactがPh3試験でIgA腎症患者の腎機能維持</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109999&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109999&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 05 Jun 2026 07:29:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109999&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 武田薬品が中国外権利を有する抗CLDN18.2 ADCが胃癌Ph3試験PFS目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109998&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109998&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 05 Jun 2026 06:53:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109998&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 急性骨髄性白血病と診断されたばかりの75歳以上の患者の経口薬のみ治療が有益</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109997&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109997&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 20:56:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109997&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] J&amp;JのFcRn遮断薬nipocalimabのSLE奏効率がプラセボを差し引きで7%上回った</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109996&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109996&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 12:08:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109996&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 腫瘍に至って活性化する二重特異性抗体を作るRegeneron社とCytomXの提携拡大</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109995&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109995&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 11:28:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109995&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Alnylam社がInceptive Nucleics社のAI技術を利用したRNA干渉薬作りに取り組む</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109994&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109994&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 10:51:21 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109994&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 来年Ph3試験が始まる男性避妊薬の開発資金1億ドル弱をContraline社が調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109993&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109993&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 10:27:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109993&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] RNA書き換えによる治療を開発しているAscidian社とLillyが提携</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109992&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109992&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 09:28:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109992&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Modernaのブンディブギョ株エボラワクチン開発にCEPIが多ければ5千万ドル提供</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109991&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109991&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 08:47:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109991&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Legend社の体内で作るCAR-Tで再発/治療抵抗性非ホジキンリンパ腫患者全員奏効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109990&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109990&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 07:19:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109990&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] GSKのKIT阻害薬velzatinibの消化管間質腫瘍初治療の暫定奏効率61%（11/18人）</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109989&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109989&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 17:01:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109989&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 老化肝臓細胞を若返らせる薬のもとを見つけたNewLimit社が4億3500万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109988&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109988&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 16:37:29 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109988&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 原発性胆汁性胆管炎患者のALPがGileadのPPARδ活性化薬Livdelziでより正常化</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109987&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109987&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 16:13:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109987&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaのER分解薬camizestrant込み乳癌治療が無増悪生存2巡目改善を示す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109986&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109986&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 15:31:38 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109986&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Abivax社の潰瘍性大腸炎薬obefazimodのPh3試験の続き試験で癌が多く発生</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109985&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109985&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 14:43:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109985&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Celcuity社の汎PI3K/mTOR阻害薬込み乳癌治療がNovartisのVijoice込み治療に勝る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109984&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109984&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 14:11:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109984&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 免疫絡み腎疾患を治療するBTK阻害薬civorebrutinib中国外権利をTravere社が取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109983&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109983&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 12:27:21 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109983&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Praxis社のナトリウムチャネル標的薬vormatrigineの焦点起始発作Ph2/3試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109982&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109982&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 11:24:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109982&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] IpsenのTazverikの血液癌多発の余波でFulcrum社の鎌状赤血球症薬pociredirが終焉</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109981&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109981&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 10:17:05 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109981&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 塩野義製薬の新型コロナウイルス（SARS-CoV-2）伝染予防薬Xocovaを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109980&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109980&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 09:48:30 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109980&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Cingulate社のデクスメチルフェニデートADHD薬CTx-1301を米国FDAが承認せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109979&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109979&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 09:31:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109979&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Henlius社の抗PD-1薬serplulimabを胃癌手術の前後に投与することで無事生存改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109978&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109978&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 08:16:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109978&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Akeso社のivonescimabの肺癌初治療全生存がBeOne社の抗PD-1薬Tevimbraに勝利</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109977&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109977&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 02 Jun 2026 17:11:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109977&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Lillyが買うKelonia社の体内仕立てCAR-Tで再発/治療抵抗性骨髄腫患者全員奏効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109976&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109976&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 02 Jun 2026 16:47:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109976&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 中国のHaisco社が見つけた治療の中国外での権利をLillyが手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109975&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109975&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 02 Jun 2026 15:26:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109975&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Oculis社のデキサメタゾン点眼薬OCS-01の糖尿病性黄斑浮腫Ph3試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109974&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109974&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 02 Jun 2026 12:56:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109974&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Edgewise社の臨床試験大詰め段階開発品を含む筋ジス事業を仏のServier社が取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109973&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109973&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 02 Jun 2026 12:23:22 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109973&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaの2品ImfinziとImjudoともう1品Lenvima込み肝癌塞栓治療でPFS延長</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109972&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109972&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 02 Jun 2026 11:28:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109972&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 短腸症候群Ph2試験段階の長持ちなGLP-2薬の国際権利をLillyがHanmi社から取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109971&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109971&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 02 Jun 2026 08:48:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109971&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Merck/KelunのTROP2標的ADCの肺癌初治療で無増悪生存が改善したPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109970&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109970&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 01 Jun 2026 16:41:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109970&amp;ref=rss</comments>
	</item>
</channel>
</rss>
